Nuwellis Marks First Commercial Sale Of QUELIMMUNE Therapy To Cincinnati Children's For Pediatric Patients Suffering From An Uncontrolled Inflammatory Response Triggered By Their Immune Systems
Portfolio Pulse from Benzinga Newsdesk
Nuwellis, Inc. (NASDAQ:NUWE) has made its first commercial sale of QUELIMMUNE therapy, developed by SeaStar Medical Holding Corporation (NASDAQ:ICU), to Cincinnati Children's for pediatric patients with uncontrolled inflammatory responses. This marks a significant advancement in pediatric critical care.
July 17, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SeaStar Medical's QUELIMMUNE therapy, distributed by Nuwellis, has been sold to Cincinnati Children's, marking a significant step in pediatric critical care.
The sale of QUELIMMUNE therapy, developed by SeaStar Medical, to a major institution like Cincinnati Children's, underlines the therapy's potential and could positively impact SeaStar Medical's market perception and future sales.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Nuwellis has made its first commercial sale of QUELIMMUNE therapy to Cincinnati Children's, marking a significant milestone in pediatric critical care.
The first commercial sale of QUELIMMUNE therapy is a significant milestone for Nuwellis, potentially boosting its market position and revenue. The positive clinical data and FDA exemption further enhance the therapy's credibility and market potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100